Stammzelltherapie bei Autoimmunerkrankungen

Zusammenfassung

In den letzten Jahren wurden mehr als 1500 Patienten weltweit wegen einer bedrohlichen, therapierefraktären Autoimmunerkrankung autologe Stammzellen transplantiert. Eine aktuelle Analyse von 900 in der EBMT Datenbank registrierten Patienten zeigte ein 5-Jahres-Überleben von 85 %. 45 % der Patienten waren nach 5 Jahren progressionsfrei. Die Therapie-assoziierte Mortalität liegt je nach Erkrankung und Konditionierungsverfahren zwischen 1 und 10 %. Neben direkt immunologisch vermittelten Effekten konnte auch gezeigt werden, dass strukturelle Veränderungen, wie Sklerose oder Rarefizierung von Hautgefäßen, nach Transplantation bei Patienten mit systemischer Sklerose reversibel waren. Mesenchymale Stammzellen sind in den letzten Jahren aufgrund ihrer immunmodulatorischen Effekte und ihrer scheinbar geringen Toxizität für verschiedene Autoimmunerkrankungen eingesetzt worden. Trotz erster ermutigender Ergebnisse stehen Daten aus kontrollierten prospektiven Studien aus.

Abstract

Over 1,500 patients world wide have received a hematopoietic stem cell transplant (HSCT) as treatment for a severe autoimmune disease. Most of these have been autologous and mostly have occurred in the past 15 years. Over 1,000 of these have been registered in the European Group for Bone Marrow Transplantation (EBMT) and European League Against Rheumatism (EULAR) combined data base. A recent retrospective analysis of 900 patients¹ showed that the majority had multiple sclerosis (n = 345) followed by systemic sclerosis (n = 175), systemic lupus erythematosus (n = 85), rheumatoid arthritis (n = 89), juvenile idiopathic arthritis (n = 65) and idiopathic cytopenic purpura (n = 37). An overall 85 % 5-year-survival and 43 % progression-free survival was seen, with 100-day-transplant-related-mortality (TRM) ranging between 1 % (rheumatoid arthritis) and 11 % (systemic lupus erythematosus and juvenile idiopathic arthritis). Around 30 % of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution. In many, e. g. systemic sclerosis, morphological improvement such as reduction of skin collagen and normalisation of microvasculature was documented, beyond any predicted known effects of intense immunosuppression alone. The high TRM was in part related to conditioning intensity, comorbidity and age, and the final risk/benefit assessment will be made after the results of the three randomised propective clinical trials are known.
Recently, multipotent mesenchymal stromal cells have been tested in various autoimmune diseases, exploiting their immune modulating properties and apparent low acute toxicity. Despite encouraging small phase I/II studies, no positive data from randomised, prospective studies are as yet available in the peer reviewed literature.

Stammzelltransplantation - Autoimmunerkrankung - hämatopoietische Stammzellen - mesenchymale Stammzellen

stem cell transplantation - autoimmune disease - hematopoietic stem cells - mesenchymal stem cells

Literatur

• 1 Alexander T, Thiel A, Rosen O. et al . Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system.  Blood. 2009;  113 214-223
• 2 Aschwanden M, Daikeler T, Jaeger K A. et al . Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease.  Ann Rheum Dis. 2008;  67 1057-1059
• 3 Bocelli-Tyndall C, Bracci L, Spagnoli G. et al . Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.  Rheumatology (Oxford). 2007;  46 403-408
• 4 Carrion F, Nova E, Ruiz C. et al . Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients.  Lupus. 2010;  19 317-322
• 5 Christopeit M, Schendel M, Foll J, Muller L P, Keysser G, Behre G. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L.  Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2008;  22 1062-1064
• 6 Ciccocioppo R, Bernardo M E, Sgarella A. et al . Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease.  Gut. 2011;  60 788-798
• 7 Daikeler T, Hugle T, Farge D. et al . Allogeneic hematopoietic SCT for patients with autoimmune diseases.  Bone Marrow Transplant. 2009;  44 27-33
• 8 Daikeler T, Labopin M, Di Gioia M. et al . Secondary autoimmune diseases occurring after HSCT for an autoimmune disease.  Blood. 2011; (Epub ahead of print); 
• 9 Duijvestein M, Vos A C, Roelofs H. et al . Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease.  Gut. 2010;  59 1662-1669
• 10 Farge D, Labopin M, Tyndall A. et al . Autologous hematopoietic stem cell transplantation for autoimmune diseases.  Haematologica. 2010;  95 284-292
• 11 Fleming J N, Nash R A, McLeod D O. et al . Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?.  PLoS One. 2008;  3 e1452
• 12 Garcia-Olmo D, Herreros D, Pascual I. et al . Expanded adipose-derived stem cells for the treatment of complex perianal fistula.  Dis Colon Rectum. 2009;  52 79-86
• 13 Horwitz E, Le Blanc K, Dominici M. et al . Clarification of the nomenclature for MSC.  Cytotherapy. 2005;  7 393-395
• 14 Karussis D, Karageorgiou C, Vaknin-Dembinsky A. et al . Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.  Arch Neurol. 2010;  67 1187-1194
• 15 Liang J, Gu F, Wang H. et al . Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE.  Nat Rev Rheumatol. 2010;  6 486-489
• 16 Liang J, Zhang H, Hua B. et al . Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis.  Mult Scler. 2009;  15 644-646
• 17 Liang J, Zhang H, Hua B. et al . Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus.  Ann Rheum Dis. 2010;  69 1423-1429
• 18 Martin I, Baldomero H, Bocelli-Tyndall C, Slaper-Cortenbach I, Passweg J, Tyndall A. The survey on cellular and engineered tissue therapies in Europe in 2009.  Tissue Engineering Part A. 2011; (Epub ahead of print); 
• 19 Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J. et al . Does mesenchymal stem cell therapy help multiple sclerosis patients?.  Iran J Immunol. 2007;  4 50-57
• 20 Muraro P A, Douek D C, Packer A. et al . Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.  J Exp Med. 2005;  201 805-816
• 21 Nevskaya T, Ananieva L, Bykovskaia S. et al . Autologous progenitor cell implantation as a novel therapeutic intervention for ischaemic digits in systemic sclerosis.  Rheumatology (Oxford). 2009;  48 61-64
• 22 Riordan N H, Ichim T E, Min W P. et al . Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis.  J Transl Med. 2009;  7 29
• 23 Sun L, Wang D, Liang J. et al . Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus.  Arthritis Rheum. 2010;  62 2467-2475
• 24 Tamm M, Gratwohl A, Tichelli A, Perruchoud A P, Tyndall A. Autologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease.  Ann Rheum Dis. 1996;  55 779-780
• 25 Tyndall A, Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases.  Bone Marrow Transplant. 2009;  43 821-828
• 26 Verrecchia F, Laboureau J, Verola O. et al . Skin involvement in scleroderma-where histological and clinical scores meet.  Rheumatology (Oxford). 2007;  46 833-841
• 27 Yamout B, Hourani R, Salti H. et al . Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis.  J Neuroimmunol. 2010;  227 185-189